Literature DB >> 12721370

NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

Du-Chu Wu1, Peter Teismann, Kim Tieu, Miquel Vila, Vernice Jackson-Lewis, Harry Ischiropoulos, Serge Przedborski.   

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder of uncertain pathogenesis characterized by a loss of substantia nigra pars compacta (SNpc) dopaminergic (DA) neurons, and can be modeled by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Both inflammatory processes and oxidative stress may contribute to MPTP- and PD-related neurodegeneration. However, whether inflammation may cause oxidative damage in MPTP and PD is unknown. Here we show that NADPH-oxidase, the main reactive oxygen species (ROS)-producing enzyme during inflammation, is up-regulated in SNpc of human PD and MPTP mice. These changes coincide with the local production of ROS, microglial activation, and DA neuronal loss seen after MPTP injections. Mutant mice defective in NADPH-oxidase exhibit less SNpc DA neuronal loss and protein oxidation than their WT littermates after MPTP injections. We show that extracellular ROS are a main determinant in inflammation-mediated DA neurotoxicity in the MPTP model of PD. This study supports a critical role for NADPH-oxidase in the pathogenesis of PD and suggests that targeting this enzyme or enhancing extracellular antioxidants may provide novel therapies for PD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12721370      PMCID: PMC156340          DOI: 10.1073/pnas.0937239100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  24 in total

1.  Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice.

Authors:  A Giovanni; B A Sieber; R E Heikkila; P K Sonsalla
Journal:  J Pharmacol Exp Ther       Date:  1991-05       Impact factor: 4.030

2.  Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity.

Authors:  S Przedborski; V Kostic; V Jackson-Lewis; A B Naini; S Simonetti; S Fahn; E Carlson; C J Epstein; J L Cadet
Journal:  J Neurosci       Date:  1992-05       Impact factor: 6.167

3.  Determination of carbonyl content in oxidatively modified proteins.

Authors:  R L Levine; D Garland; C N Oliver; A Amici; I Climent; A G Lenz; B W Ahn; S Shaltiel; E R Stadtman
Journal:  Methods Enzymol       Date:  1990       Impact factor: 1.600

4.  NADPH oxidase contributes directly to oxidative stress and apoptosis in nerve growth factor-deprived sympathetic neurons.

Authors:  S P Tammariello; M T Quinn; S Estus
Journal:  J Neurosci       Date:  2000-01-01       Impact factor: 6.167

5.  Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.

Authors:  S Przedborski; Q Chen; M Vila; B I Giasson; R Djaldatti; S Vukosavic; J M Souza; V Jackson-Lewis; V M Lee; H Ischiropoulos
Journal:  J Neurochem       Date:  2001-01       Impact factor: 5.372

6.  Selective retention of MPP+ within the monoaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study.

Authors:  M Herkenham; M D Little; K Bankiewicz; S C Yang; S P Markey; J N Johannessen
Journal:  Neuroscience       Date:  1991       Impact factor: 3.590

7.  1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles.

Authors:  E Hasegawa; K Takeshige; T Oishi; Y Murai; S Minakami
Journal:  Biochem Biophys Res Commun       Date:  1990-08-16       Impact factor: 3.575

8.  The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity.

Authors:  J Lotharius; K L O'Malley
Journal:  J Biol Chem       Date:  2000-12-08       Impact factor: 5.157

9.  Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice.

Authors:  J B Schulz; R T Matthews; M M Muqit; S E Browne; M F Beal
Journal:  J Neurochem       Date:  1995-02       Impact factor: 5.372

10.  Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease.

Authors:  Hui-Ming Gao; Janwei Jiang; Belinda Wilson; Wanqin Zhang; Jau-Shyong Hong; Bin Liu
Journal:  J Neurochem       Date:  2002-06       Impact factor: 5.372

View more
  244 in total

Review 1.  New insights into the mechanisms of diabetic neuropathy.

Authors:  Andrea M Vincent; Eva L Feldman
Journal:  Rev Endocr Metab Disord       Date:  2004-08       Impact factor: 6.514

2.  Occupational exposure to welding fume among welders: alterations of manganese, iron, zinc, copper, and lead in body fluids and the oxidative stress status.

Authors:  Guojun Jane Li; Long-Lian Zhang; Ling Lu; Ping Wu; Wei Zheng
Journal:  J Occup Environ Med       Date:  2004-03       Impact factor: 2.162

Review 3.  NADPH oxidases: novel therapeutic targets for neurodegenerative diseases.

Authors:  Hui-Ming Gao; Hui Zhou; Jau-Shyong Hong
Journal:  Trends Pharmacol Sci       Date:  2012-04-11       Impact factor: 14.819

4.  Chronic dichlorvos exposure: microglial activation, proinflammatory cytokines and damage to nigrostriatal dopaminergic system.

Authors:  B K Binukumar; Amanjit Bal; Kiran Dip Gill
Journal:  Neuromolecular Med       Date:  2011-10-04       Impact factor: 3.843

Review 5.  Heterogeneity of CNS myeloid cells and their roles in neurodegeneration.

Authors:  Marco Prinz; Josef Priller; Sangram S Sisodia; Richard M Ransohoff
Journal:  Nat Neurosci       Date:  2011-09-27       Impact factor: 24.884

6.  A macrophage-nanozyme delivery system for Parkinson's disease.

Authors:  Elena V Batrakova; Shu Li; Ashley D Reynolds; R Lee Mosley; Tatiana K Bronich; Alexander V Kabanov; Howard E Gendelman
Journal:  Bioconjug Chem       Date:  2007-08-31       Impact factor: 4.774

7.  Brain angiotensin and dopaminergic degeneration: relevance to Parkinson's disease.

Authors:  Jose L Labandeira-Garcia; Jannette Rodriguez-Pallares; Ana I Rodríguez-Perez; Pablo Garrido-Gil; Begoña Villar-Cheda; Rita Valenzuela; Maria J Guerra
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

Review 8.  Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance.

Authors:  Chun Zhou; Yong Huang; Serge Przedborski
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

9.  Minocycline Rescues from Zinc-Induced Nigrostriatal Dopaminergic Neurodegeneration: Biochemical and Molecular Interventions.

Authors:  Vinod Kumar; Brajesh Kumar Singh; Amit Kumar Chauhan; Deepali Singh; Devendra Kumar Patel; Chetna Singh
Journal:  Mol Neurobiol       Date:  2015-03-13       Impact factor: 5.590

10.  Tauroursodeoxycholic Acid Protects Against Mitochondrial Dysfunction and Cell Death via Mitophagy in Human Neuroblastoma Cells.

Authors:  Inês Fonseca; Gisela Gordino; Sara Moreira; Maria João Nunes; Carla Azevedo; Maria João Gama; Elsa Rodrigues; Cecília Maria Pereira Rodrigues; Margarida Castro-Caldas
Journal:  Mol Neurobiol       Date:  2016-10-03       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.